A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients
NCT03427008 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2021-09-23
Summary
The investigators are interested in whether or not the use of a mobile health (mHealth) application increases the rate of immunosuppression medication adherence among adult kidney transplant recipients. The investigators aim to test this by randomly assigning transplant recipients to the intervention (use of an mHealth app to manage and track their immunosuppression regimen) or control arm (standard of care) upon discharge from their initial transplant hospitalization, and tracking medication adherence over time. The study population will be approximately 50 adult kidney transplant recipients at the Johns Hopkins Hospital.
Conditions
- Medication Adherence
- Transplant; Kidney
Interventions
- OTHER
-
mHealth Intervention
The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Macey Henderson, JD,PhD · Johns Hopkins University
-
Daniel Brennan, MD · Johns Hopkins University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 22 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-30
- Primary Completion
- 2020-11-12
- Completion
- 2020-11-12
Countries
- United States
Study Locations
More Related Trials
-
Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients
NCT00371904 ·Status: UNKNOWN ·Phase: PHASE2
-
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
NCT04104438 ·Status: COMPLETED ·Phase: PHASE4
-
Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant
NCT00167791 ·Status: WITHDRAWN ·Phase: NA
-
Improving Medication Adherence in Adolescents Who Had a Liver Transplant
NCT03691220 ·Status: COMPLETED ·Phase: NA
-
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
NCT04473924 ·Status: WITHDRAWN ·Phase: PHASE2
-
Intervention to Improve Adherence in Teen Kidney Transplant
NCT01356277 ·Status: COMPLETED ·Phase: NA
-
Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients
NCT02426502 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Teen Adherence in KidnEy Transplant, Improving Tracking To Optimize Outcomes (Stage 1)
NCT02910661 ·Status: COMPLETED
-
Medication Adherence in Children Who Had a Liver Transplant
NCT01154075 ·Status: COMPLETED
-
Bortezomib in Rejection of Kidney Transplants
NCT02201576 ·Status: COMPLETED ·Phase: PHASE2
-
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
NCT01905514 ·Status: UNKNOWN ·Phase: NA
-
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
NCT00183248 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
NCT02130817 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
NCT02495077 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
NCT03221842 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
NCT01154387 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Safety and Efficacy Study of Rituximab in Renal Transplantation
NCT00255593 ·Status: COMPLETED ·Phase: PHASE1
-
Iguratimod in Kidney Transplant Recipients
NCT02839941 ·Status: UNKNOWN ·Phase: NA
-
Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
NCT00522548 ·Status: TERMINATED ·Phase: PHASE4
-
Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation
NCT00579592 ·Status: TERMINATED ·Phase: NA
-
Myfortic vs. Cellcept in Kidney Transplant Recipients
NCT00533624 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Adherence to Immunosuppressive Therapy Liver Transplant Recipients
NCT01959308 ·Status: UNKNOWN
-
Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation
NCT01035593 ·Status: WITHDRAWN ·Phase: PHASE2
-
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
NCT03994783 ·Status: TERMINATED ·Phase: PHASE3
-
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
NCT00986947 ·Status: TERMINATED ·Phase: PHASE2